DRUG WARNING: Boceprevir (Victrelis™)

By /

On February 6, 2012, Merck and Co, Inc. in collaboration with the U.S. Food and Drug Administration (FDA) issued a Dear Healthcare Professional letter regarding the potential for lowered drug concentrations when combining certain ritonavir-boosted HIV protease-inhibitors (atazanavir, darunavir, lopinavir) and the hepatitis C protease-inhibitor, boceprevir. Health care providers who are treating patients with this combination are advised to closely monitor patients for HIV viral rebound and hepatitis C treatment response.

Link not available. Boceprevir is no longer marketed in Canada (January 2017)

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search